UNLIMITED TURBO BULL - VERTEX PHARMACEUTICALS | Market Closed - Euronext Paris 10:00:00 20/05/2024 pm IST | ||
| 4.076 EUR | +1.54% |
|
| Current month | +27.06% | ||
| 1 month | +26.35% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 20/24/20 | 4.076 | +1.54% |
| 17/24/17 | 4.014 | +2.32% |
| 16/24/16 | 3.923 | +0.62% |
| 15/24/15 | 3.899 | +6.01% |
| 14/24/14 | 3.678 | -2.10% |
Real-time Euronext Paris
Last update May 20, 2024 at 10:00 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| KP24S | |
| ISIN | DE000SH2DY64 |
| Date issued | 02/02/2022 |
| Strike | 225.5 $ |
| Maturity | Unlimited |
| Parity | 50 : 1 |
| Emission price | 0.91 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.53 € |
|---|---|
| Lowest since issue | 0.596 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
445.9
USD
Average target price
462.6
USD
Spread / Average Target
+3.74%
- Stock Market
- Certificates
- KP24S Certificat
